Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion…

Posted: March 8, 2025 at 2:45 am

Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments

Read more:
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion...

Related Posts